IOVA Iovance Biotherapeutics, Inc. stock chart & analysis
Conviction 45HealthcareScan · Fri, Nov 6, 2026Iovance Biotherapeutics, Inc. (IOVA) closed at $8.04 (+3.88%) on Nov 6, 2026. Price is below its 50-day and above its 200-day moving average. RSI(14) 33, RS Rating 99, -47.7% from its 52-week high, +194.5% year to date. Sector: Healthcare · Biological Products, (No Diagnostic Substances).
Why IOVA moved
From the StockSetups movers recaps that covered IOVA, newest first. A recap states what was known that day.
- Close+42.4%
Iovance reported record second-quarter 2026 revenue of approximately $99 million, according to the company's earnings release covered by Yahoo Finance on August 6.
Top Stock Movers Today — August 6, 2026: Why WYHG, IOVA, HNST, ASPN & INSM Surged →
Financials as of Wed, Sep 30, 2026 · quarterly.
IOVA technical analysis
Trend
IOVA's moving averages are mixed — no clean uptrend or downtrend. It closed 29.3% below the 50-day ($11.38) and 34.4% above the 200-day ($5.98). ADX(14) at 42 points to a strong, established trend. It meets 6 of 8 trend-template criteria.
Momentum
RSI(14) is 33, in the bearish half of its range. The MACD histogram is negative. Its RS Rating of 99 puts its weighted 12-month performance ahead of about 99% of the US market.
Volume and volatility
Volume on the latest session ran 0.9× its 20-day average. It trades about $171.4M a day on average. ATR(14) is $1.10, 13.7% of price — its typical daily range. On-balance volume is trending down. Chaikin Money Flow (-0.23) shows distribution.
Key levels
The chart pattern's support is $9.99 and its resistance $15.34. The 52-week range is $2.08 to $15.37; price is 47.7% below the high and 286.5% above the low. The VWAP anchored at the 52-week high is $10.22, above price.
Performance
IOVA returned -5.2% (1 week), -39.6% (1 month), +25.6% (3 months), +122.1% (6 months), +344.2% (1 year), +194.5% (year to date).
About Iovance Biotherapeutics, Inc.
Iovance Biotherapeutics Inc is a clinical-stage biopharmaceutical company, pioneering a transformational approach to treating cancer by harnessing the human immune system's ability to recognize and destroy diverse cancer cells using therapies personalized for each patient. The company is preparing for potential U.S. regulatory approvals and commercialization of the first autologous T-cell therapy to address a solid tumor cancer. It operates in one segment, focusing on innovating, developing, and commercializing therapies using its autologous TIL cell therapies for patients with solid tumor cancers. Geographically, the company operates in United States and Rest of the World.
Biological Products, (No Diagnostic Substances) · Listed 2010 · 975 employees
Recent news
- Iovance Biotherapeutics: Q3 Earnings SnapshotYahoo Finance · Thu, Nov 5, 2026
- Iovance Biotherapeutics Reports Record Third Quarter 2026 Revenue of ~$122M, Business Achievements, and Corporate UpdatesYahoo Finance · Thu, Nov 5, 2026
- Iovance Biotherapeutics, Inc. (IOVA) Seasonal returns chartYahoo Finance Australia · Wed, Nov 4, 2026
- Iovance earnings on deck: Can Amtagvi sustain launch momentum? By Investing.comInvesting.com India · Wed, Nov 4, 2026
Insider activity
SEC Form 4 transactions in IOVA
| Insider | Side | Shares | Value | Traded | Filed |
|---|---|---|---|---|---|
Kirby Daniel Gordon Chief Commercial Officer · Common Stock · 2026-08-10 | Exercise | 10K | — | 2026-08-10 | 2026-08-12 |
Kirby Daniel Gordon Chief Commercial Officer · Common Stock · 2026-08-10 | Tax | 2.44K | $16K | 2026-08-10 | 2026-08-12 |
Kirby Daniel Gordon Chief Commercial Officer · Restricted Stock Units · 2026-08-10 | Exercise | 10K | — | 2026-08-10 | 2026-08-12 |
Roche Corleen M. Chief Financial Officer · Common Stock · 2026-08-06 | Exercise | 49.99K | — | 2026-08-06 | 2026-08-10 |
Roche Corleen M. Chief Financial Officer · Common Stock · 2026-08-06 | Tax | 21.24K | $132K | 2026-08-06 | 2026-08-10 |
Roche Corleen M. Chief Financial Officer · Restricted Stock Units · 2026-08-06 | Exercise | 49.99K | — | 2026-08-06 | 2026-08-10 |
Countouriotis Athena Director · Deferred Restricted Stock Unit · 2026-06-16 | Grant | 90.32K | — | 2026-06-16 | 2026-06-18 |
Dukes Iain D. Director · Deferred Restricted Stock Unit · 2026-06-16 | Grant | 180.63K | — | 2026-06-16 | 2026-06-18 |
Puri Raj K. Chief Regulatory Officer · Restricted Stock Units · 2026-06-16 | Grant | 15K | — | 2026-06-16 | 2026-06-18 |
Maynard Ryan D Director · Deferred Restricted Stock Unit · 2026-06-16 | Grant | 90.32K | — | 2026-06-16 | 2026-06-18 |
SEC filings
EDGAR filings in IOVA · 10 recent
Get daily signals & real-time alerts.
StockSetups scans ~12,300 US stocks & ETFs after every close and sorts every long setup into four ranked lanes — each with a trade plan — plus an always-on engine firing 35+ real-time intraday alerts. Free for 7 days, no credit card.
Start free — 7-day trial, no card →Free daily signals by email. Top 3 setups per lane after every close. No account needed.
Unsubscribe anytime · Privacy
Educational data, not financial advice. Patterns, levels and the trade plan are algorithmic, not a recommendation to trade.